Published in Ophthalmology on May 01, 2012
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med (2015) 7.08
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 3.85
Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology (2012) 2.68
Mechanisms of age-related macular degeneration. Neuron (2012) 2.62
Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy. Br J Ophthalmol (2013) 2.26
Immunology of age-related macular degeneration. Nat Rev Immunol (2013) 2.14
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology (2016) 2.04
Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol (2013) 1.97
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.95
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.76
Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 1.57
Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2014) 1.45
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol (2014) 1.42
Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes. Clin Ophthalmol (2016) 1.42
Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol (2014) 1.41
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol (2014) 1.41
Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol (2012) 1.40
Quantifying disrupted outer retinal-subretinal layer in SD-OCT images in choroidal neovascularization. Invest Ophthalmol Vis Sci (2014) 1.39
Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis. Ophthalmic Epidemiol (2016) 1.39
Ultrahigh-speed swept-source OCT angiography in exudative AMD. Ophthalmic Surg Lasers Imaging Retina (2014) 1.35
Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab (2013) 1.34
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol (2014) 1.32
Cortical responses elicited by photovoltaic subretinal prostheses exhibit similarities to visually evoked potentials. Nat Commun (2013) 1.32
Restoring visual function to blind mice with a photoswitch that exploits electrophysiological remodeling of retinal ganglion cells. Neuron (2014) 1.29
Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefes Arch Clin Exp Ophthalmol (2014) 1.28
Landmark matching based retinal image alignment by enforcing sparsity in correspondence matrix. Med Image Anal (2013) 1.28
Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One (2013) 1.23
Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol (2014) 1.20
Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol (2014) 1.20
Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol (2013) 1.16
The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary. Eye (Lond) (2013) 1.15
Mechanism of inflammation in age-related macular degeneration. Mediators Inflamm (2012) 1.14
Drug-induced uveitis. J Ophthalmic Inflamm Infect (2013) 1.11
Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol (2015) 1.09
Optical Coherence Tomography Angiography of Asymptomatic Neovascularization in Intermediate Age-Related Macular Degeneration. Ophthalmology (2016) 1.09
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF TIME COURSE OF CHOROIDAL NEOVASCULARIZATION IN RESPONSE TO ANTI-ANGIOGENIC TREATMENT. Retina (2015) 1.09
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 1.04
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization. Eye (Lond) (2013) 1.03
Myopic choroidal neovascularisation: current concepts and update on clinical management. Br J Ophthalmol (2014) 1.02
Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol (2014) 1.02
Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye (Lond) (2014) 1.01
Factors affecting visual outcome of myopic choroidal neovascularization treated with verteporfin photodynamic therapy. Int J Ophthalmol (2013) 1.00
Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ (2012) 1.00
Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open (2013) 1.00
Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology (2014) 0.99
Recent developments in the treatment of age-related macular degeneration. J Clin Invest (2014) 0.99
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clin Interv Aging (2013) 0.99
Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series. Graefes Arch Clin Exp Ophthalmol (2013) 0.99
Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int (2014) 0.98
Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther (2013) 0.97
Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab? Eye (Lond) (2012) 0.96
Comparative effectiveness of bevacizumab and ranibizumab in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol (2015) 0.95
Parainflammation, chronic inflammation, and age-related macular degeneration. J Leukoc Biol (2015) 0.94
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open (2014) 0.94
Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period. Health Aff (Millwood) (2014) 0.94
[Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany]. Ophthalmologe (2015) 0.93
What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol (2013) 0.93
Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studies. PLoS One (2014) 0.93
Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD. J Ophthalmol (2016) 0.92
Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: Findings from a Cochrane Systematic Review. Ophthalmology (2015) 0.92
VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol (2014) 0.92
The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefes Arch Clin Exp Ophthalmol (2014) 0.91
Ocular delivery of macromolecules. J Control Release (2014) 0.91
Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano (2013) 0.91
Optical coherence tomography in retinopathy of prematurity: looking beyond the vessels. Clin Perinatol (2013) 0.90
Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration - monthly injections versus pro re nata. Graefes Arch Clin Exp Ophthalmol (2013) 0.90
Rate of vision loss in neovascular age-related macular degeneration explored. Graefes Arch Clin Exp Ophthalmol (2014) 0.90
Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls. Curr Eye Res (2013) 0.89
Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future. Br J Clin Pharmacol (2014) 0.89
Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor. Korean J Ophthalmol (2015) 0.89
The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review. BMJ Open (2014) 0.89
Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin. J Ocul Pharmacol Ther (2013) 0.89
Ranibizumab in diabetic macular edema. World J Diabetes (2013) 0.89
Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology (2014) 0.89
Acute sterile endophthalmitis following intravitreal bevacizumab: case series. Clin Ophthalmol (2014) 0.89
The sustained delivery of resveratrol or a defined grape powder inhibits new blood vessel formation in a mouse model of choroidal neovascularization. Molecules (2014) 0.89
Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab. Korean J Ophthalmol (2014) 0.88
Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proc Natl Acad Sci U S A (2016) 0.88
Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration. Br J Ophthalmol (2015) 0.88
Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med (2014) 0.88
Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis. Int J Ophthalmol (2014) 0.88
Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 0.88
Quality of bevacizumab compounded for intravitreal administration. Eye (Lond) (2013) 0.87
Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic review. BMJ Open (2015) 0.87
Fcγ receptor upregulation is associated with immune complex inflammation in the mouse retina and early age-related macular degeneration. Invest Ophthalmol Vis Sci (2014) 0.87
Clinical characteristics and current treatment of age-related macular degeneration. Cold Spring Harb Perspect Med (2014) 0.87
Lateral and axial measurement differences between spectral-domain optical coherence tomography systems. J Biomed Opt (2014) 0.87
Age-Related Macular Degeneration: Advances in Management and Diagnosis. J Clin Med (2015) 0.87
Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology (2014) 0.87
Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. Clin Ophthalmol (2015) 0.87
Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes. Graefes Arch Clin Exp Ophthalmol (2014) 0.86
Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2014) 0.86
Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population. Clin Ophthalmol (2015) 0.86
A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV. Graefes Arch Clin Exp Ophthalmol (2014) 0.86
Complement pathway biomarkers and age-related macular degeneration. Eye (Lond) (2015) 0.86
Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol (2015) 0.86
The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care. Eye (Lond) (2016) 0.86
Longitudinal data analysis for discrete and continuous outcomes. Biometrics (1986) 60.93
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med (2006) 20.84
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol (2001) 7.60
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA (2008) 7.13
Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol (1993) 3.78
Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol (2009) 3.43
Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol (2011) 3.24
Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology (2003) 2.47
Complement factor H polymorphism in age-related macular degeneration. Science (2005) 31.10
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med (2008) 17.21
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2010) 10.28
A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol (2003) 9.99
Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology (2003) 8.98
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med (2015) 7.08
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 6.71
Comparison of preschool vision screening tests as administered by licensed eye care professionals in the Vision In Preschoolers Study. Ophthalmology (2004) 4.98
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology (2006) 4.72
Evaluation of image artifact produced by optical coherence tomography of retinal pathology. Am J Ophthalmol (2005) 4.54
The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol (2005) 4.46
Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2011) 4.15
Age-related macular degeneration. Lancet (2008) 3.34
Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology (2005) 3.28
Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol (2009) 3.21
Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol (2003) 3.17
Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol (2008) 3.14
Prevalence of refractive error in the United States, 1999-2004. Arch Ophthalmol (2008) 3.06
The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol (2007) 3.02
Panretinal photocoagulation for proliferative diabetic retinopathy. N Engl J Med (2011) 2.98
Diabetic retinopathy. Diabetes Care (2004) 2.97
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol (2010) 2.96
Evaluation of artifacts associated with macular spectral-domain optical coherence tomography. Ophthalmology (2010) 2.92
Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology (2013) 2.82
Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology (2007) 2.69
Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology (2012) 2.68
Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology (2012) 2.48
Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol (2007) 2.44
Darkness and near work: myopia and its progression in third-year law students. Ophthalmology (2002) 2.33
Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol (2003) 2.25
Retinal pigment epithelial changes after macular hole surgery with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol (2002) 2.20
Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology (2004) 2.19
Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology (2012) 2.19
Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol (2007) 2.18
Utility of intraoperative optical coherence tomography during vitrectomy surgery for vitreomacular traction syndrome. Retina (2014) 2.15
The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. Arch Ophthalmol (2007) 2.12
Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology (2008) 2.10
Treatment choice for diabetic macular edema. N Engl J Med (2015) 2.06
Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology (2004) 1.96
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.95
Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures. Exp Eye Res (2005) 1.94
The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Arch Ophthalmol (2008) 1.93
Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci (2005) 1.92
Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol (2009) 1.85
Identifying and eliminating the roadblocks to comparative-effectiveness research. N Engl J Med (2010) 1.84
In vivo human choroidal thickness measurements: evidence for diurnal fluctuations. Invest Ophthalmol Vis Sci (2008) 1.83
Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci (2005) 1.80
Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol (2011) 1.80
Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol (2013) 1.78
Risk assessment model for development of advanced age-related macular degeneration. Arch Ophthalmol (2011) 1.75
Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology (2009) 1.74
Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.73
Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.70
Risk of advanced age-related macular degeneration after cataract surgery in the Age-Related Eye Disease Study: AREDS report 25. Ophthalmology (2008) 1.69
Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. Am J Ophthalmol (2006) 1.66
The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology (2012) 1.66
Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma. Am J Ophthalmol (2010) 1.66
Final visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol (2010) 1.64
Blindness and visual impairment: a public health issue for the future as well as today. Arch Ophthalmol (2004) 1.63
Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology (2008) 1.60
Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology (2007) 1.59
Stereoacuity of preschool children with and without vision disorders. Optom Vis Sci (2014) 1.58
Retinopathy and cognitive impairment in adults with CKD. Am J Kidney Dis (2012) 1.58
Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci (2008) 1.58
Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 1.57
Incidence of exudative age-related macular degeneration among elderly Americans. Ophthalmology (2003) 1.54
Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol (2009) 1.53
Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology (2011) 1.52
Progression to severe retinopathy predicted by retinal vessel diameter between 31 and 34 weeks of postconception age. Arch Ophthalmol (2007) 1.52
Prevalence of posterior subcapsular cataracts in volunteer cytapheresis donors. Transfusion (2010) 1.51
Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema. Ophthalmology (2013) 1.51
An electronic medical records system for clinical research and the EMR EDC interface. Invest Ophthalmol Vis Sci (2007) 1.48
Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: submacular surgery trials report no. 7. Arch Ophthalmol (2005) 1.47
Association of risk factors for choroidal neovascularization in age-related macular degeneration with decreased foveolar choroidal circulation. Am J Ophthalmol (2010) 1.47
Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A (2011) 1.47
Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina. Retina (2007) 1.46
Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. Ophthalmology (2009) 1.46
Comparison of spectral- and time-domain optical coherence tomography for retinal thickness measurements in healthy and diseased eyes. Am J Ophthalmol (2009) 1.39